Gilead's CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis' Kymriah was given a green light.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.